Cuprina Holdings (Cayman) Limited is trading 31% down at $5.80 as the stock undergoes a period of normalization and profit-taking following a massive rally triggered by U.S. regulatory clearance.
- Shares had previously surged 112% to $8.41 on June 15, 2026, after the company received FDA clearance for its maggot-based biological wound treatment.
- The current pre-market decline reflects a correction from extreme speculative gains, with no new negative catalysts or news reported to justify the drop.
- The recent volatility briefly pushed the company's market valuation to approximately $6.5 million.